A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period.
* Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
RA Only:
* Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA
* Presence of rheumatoid factor or ACPA above the ULN
* Confirmation of at least moderate active disease at screening with the presence of at least 6 swollen and 6 tender joints at screening using the 68 (tender)/66 (swollen) joint count OR the presence of at least 3 joints with active synovitis via MRI assessment.
SLE Only:
* Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria for SLE
* Positive ANA\>=1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double standard DNA (dsDNA) or anti-Smith (Sm).
Exclusion Criteria:
* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted.
* Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of CPTX2309.
RA Only:
\- Participants diagnosed with Felty's syndrome
SLE Only:
* Active neuropsychiatric SLE, as defined by the CNS portion of SLEDAI at Screening, or signs of symptoms of neuropsychiatric SLE within 6 months prior to Screening (lupus headache permissible)
* Note: Other protocol-defined inclusion/exclusion criteria apply
Primary outcome measure(s)
Number of participants with changes in the safety parameters — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Number of participants with clinical laboratory assessment abnormalities — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Number of participants with changes in the vital signs — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Number of participants with changes in the ECG — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Number of participants who develop anti-drug antibodies (ADAs) and Circulating Immune Complex (CIC) formation — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Part A and B: Number of participants with change from baseline in vaccine antibody titers — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants.
Changes in serum cytokine and chemokine levels that are known to be associated with CAR-T cell therapy related toxicity — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Change from baseline in soluble immunoglobulins (Ig) — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.
Part C and D: Change from baseline in vaccination-induced antibody titers — Up to approximately 1 Year To evaluate the safety and tolerability of CPTX2309 administered to participants with moderate to severe RA and SLE.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.